Why the study?
Patients with cancer have an increased risk of recurrent venous thromboembolism even on anticoagulation, risk assessment models require better validation, and managing recurrence while balancing bleeding risk remains challenging.
This review summarizes literature and provides suggestions on management strategies for recurrent cancer-associated thrombosis, balancing VTE recurrence and bleeding risks.
Answers are grounded in this paper and cite their sources.
Calls for heightened vigilance and individualized risk assessment in cancer; confirms unmet need for superior antithrombotic strategies.
Patients with cancer have an increased risk of venous thromboembolism (VTE), often even while on therapeutic dose of anticoagulation. Recent randomized controlled trials show that the 6-month rate of recurrent VTE is 5-8% during anticoagulation. Multiple risk factors are reported to be associated with recurrent cancer-associated thrombosis, including history of VTE, poor Eastern Cooperative Oncology Group performance status, metastatic diseases, and certain cancer types. Several risk assessment models are derived, but better validation is needed before clinical use. Management of patients with recurrent VTE while on anticoagulation is challenging. Necessary considerations include both the risk of further VTE recurrence and the risk of bleeding. In this review, we will summarize pertinent literature and provide suggestions on the management strategies in patients with recurrent cancer-associated thrombosis.
No takes yet. Share an insight, caveat, or question.
Nisio et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: